HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
WORCESTER, Mass., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, today announced the closing of a Series A financing round. Nemucore plans to use the proceeds of the financing to advance NMI-900, a potential "best-in-class" therapeutic into a Phase 2b trial in ovarian cancer, the development and expansion of its innovative oncology pipeline and for general corporate purposes. Financial terms were not disclosed.
“We are pleased to close this financing, which is key to progressing our lead program into the next stage of clinical development,” said Timothy P. Coleman, Ph.D., Chairman, Chief Executive Officer and President of Nemucore. “This financing recognizes the capital efficiency of our organization, as we have successfully advanced novel therapies into the clinic for difficult-to-treat cancers. We believe the support of our investors is a strong endorsement of the leadership team and positions Nemucore’s assets for strategic growth and investment.”
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential "best-in-class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in mid-2016. Two additional candidates are anticipated to enter clinical trial development later in 2016, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at www.nemucore.com.
Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen Bergman (650) 323-1717 [email protected] Jen LaVin (207) 360-0473 [email protected]
